1 Wall Street Analyst Says Tilray Stock Could Jump Over 40%. Should You Believe It?

Roth Capital upgraded Tilray to buy and set a $10 price target, implying more than 40% upside from current levels. Bullish arguments include 8% year-over-year growth in Canadian cannabis net revenue, 70% growth in international cannabis revenue to $24.1 million, and 22% growth in beverage revenue to $42.6 million. However, Tilray still missed consensus revenue estimates and faces ongoing cannabis industry headwinds, limiting near-term conviction.

Analysis

TLRY is effectively a leveraged call option on a loosening of cannabis operating conditions, but the stock’s asymmetric upside only works if the market starts pricing in a cleaner path to sustained EBITDA improvement. The second-order read is that the beverage buildout matters less for near-term earnings than for multiple expansion: it gives equity holders a “normal consumer platform” narrative that can partially offset cannabis stigma and valuation compression. If management can keep gross margin stable while mix shifts toward beverages and international, the market could rerate the name before any meaningful U.S. federal reform.

The bigger competitive implication is that stronger Canadian and international share gains tend to come at the expense of smaller, undercapitalized operators that cannot fund distribution or brand investment through a downcycle. That means a prolonged industry squeeze could actually improve TLRY’s relative positioning even if absolute demand stays weak. The flip side is that beverage execution is not automatically accretive; integration and brand-building spend can widen losses for multiple quarters before synergies show up, especially if promotional intensity rises.

The key risk is timing mismatch: sentiment can move on “hope” in weeks, but fundamentals need months. Any disappointment on revenue or margin in the next 1-2 quarters would likely snap the stock back because the current setup is already leaning on multiple narratives at once—Canada stability, international growth, and beverage optionality. The market is missing that TLRY’s upside is likely less about a standalone 40% earnings-driven revaluation and more about sector beta plus a short-covering burst; without a broader cannabis tape, the rally likely stalls well below the analyst target.

Key Decisions for Investors

• Use TLRY as a tactical trading long only, not a core hold: consider buying 3-6 month calls or a call spread to capture a sector re-rating while capping downside if the next print disappoints; avoid outright equity until execution improves.
• If already long TLRY, trim into strength on any 15-20% pop over 1-2 weeks; the stock is more likely to re-rate on sentiment than on durable fundamental acceleration, so upside is front-loaded and fragile.
• Relative-value idea: long TLRY vs short a smaller-cap Canadian cannabis peer basket if liquidity allows; the thesis is that scale and international distribution should preserve share while weaker operators get squeezed by funding costs and promo pressure.
• Watch for a catalyst stack over the next 1-2 earnings cycles: another quarter of international revenue growth above 50% YoY plus beverage margins holding steady would justify adding; if either stalls, exit quickly because the multiple is likely to compress first and ask questions later.
• For diversified cannabis exposure, prefer an ETF over single-name exposure if the goal is policy optionality rather than idiosyncratic execution risk; TLRY is the higher-beta expression, but also the most dependent on a clean macro/regulatory surprise.